fbpx

Resources

Apr 13, 2023

ICYMI: Study finds Americans over the age of 40 lack sight-saving knowledge of AMD

by: David Hutton A new survey of Americans 40 and older reveals a concerning lack of knowledge about the leading cause of blindness and vision loss among older adults, age-related…

ICYMI: Study finds Americans over the age of 40 lack sight-saving knowledge of AMD

Apr 13, 2023

Know About The Health Benefits Of Prunes

Four to five prunes a day provide approximately 280 mg of potassium or about 12% of your daily required requirement. By: ABP News Bureau New Delhi: Prunes, sometimes known as dried plums,…

Know About The Health Benefits Of Prunes

Apr 13, 2023

Target ‘Inflammaging’ to Promote Healthy Aging

by: April 11, 2023 / By Julie Poteet, OD, MS, CNS, FONS Doctors are taught that there are two types of inflammation, acute and chronic. Acute inflammation is characterized by short duration…

Target ‘Inflammaging’ to Promote Healthy Aging

Mar 15, 2023

Seeing Clearly

By Claire Zulkey How a routine vision check can save your life Jackie Memije assumed she was just stressed out, so she ignored her symptoms. The whooshing in the ears,…

Seeing Clearly

Mar 15, 2023

How Melatonin Might Impact Your Eye Health

BY BETH BRADFORD Melatonin works in your brain to regulate your sleep cycle because it kicks in when there’s less light. Although your body produces it naturally, many of us take…

How Melatonin Might Impact Your Eye Health

Mar 15, 2023

LumiThera Announces Sustained Vision Improvement for 24 months in Dry Age-Related Macular Degeneration Subjects from US LIGHTSITE III Clinical Trial Data

Press Release March 15, 2023, 07:17 AM Eastern Daylight Time SEATTLE–(BUSINESS WIRE)–LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the 24-…

LumiThera Announces Sustained Vision Improvement for 24 months in Dry Age-Related Macular Degeneration Subjects from US LIGHTSITE III Clinical Trial Data

Mar 14, 2023

Ocugen submits NDA with FDA to initiate phase 1 clinical trial evaluating OCU200 for treatment of DME

by: David Hutton The regulatory milestone fulfills the company’s goal to file the IND for OCU200 within the first quarter of 2023. Ocugen Inc. today announced that it has submitted…

Ocugen submits NDA with FDA to initiate phase 1 clinical trial evaluating OCU200 for treatment of DME

Mar 7, 2023

MacuHealth & Macular Degeneration Association announce partnership

Press Release  The Macular Degeneration Association and MacuHealth Announce Partnership   BIRMINGHAM, Mich., March 07, 2023 – The Macular Degeneration Association, an organization dedicated to educating age-related macular degeneration (AMD)…

MacuHealth & Macular Degeneration Association announce partnership

Mar 7, 2023

Eyedaptic unveils the EYE5 glasses with EyeSwitch™

The latest model in the Eyedaptic product showcase boasts comfort without sacrificing usability and adds brand-new artificial intelligence features. Laguna Hills, CA — October 24, 2022 —Eyedaptic, Inc., is excited to…

Eyedaptic unveils the EYE5 glasses with EyeSwitch™

Feb 28, 2023

February as Low Vision and Age-Related Macular Degeneration (AMD) Awareness Month.

These conditions impact millions (AMD alone affects 196M) of individuals worldwide. This month highlights the importance of those with low vision seeking the appropriate care and management. Low Vision FAQ My…

February as Low Vision and Age-Related Macular Degeneration (AMD) Awareness Month.

Feb 28, 2023

AFLIBERCEPT 8 MG BLA FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA ACCEPTED FOR FDA PRIORITY REVIEW

Breaking News BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA® (aflibercept) Injection, with vast majority of patients maintaining extended dosing regimens through 48 weeks If approved, aflibercept…

AFLIBERCEPT 8 MG BLA FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA ACCEPTED FOR FDA PRIORITY REVIEW

Feb 22, 2023

Researchers identify a new genetic risk factor for age-related macular degeneration

Reviewed by Emily Henderson, B.SC. Researchers at Tel Aviv University identified a new genetic risk factor for the complex eye disease AMD (Age-related Macular Degeneration), a leading cause for loss…

Researchers identify a new genetic risk factor for age-related macular degeneration

Feb 19, 2023

FDA Approves Apellis’ SYFOVRE™, for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Newly approved treatment for Geographic Atrophy by FDA Geographic atrophy (GA) is the advanced form of dry age-related macular degeneration (AMD) which causes blindness in one million people in the…

FDA Approves Apellis’ SYFOVRE™, for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Feb 13, 2023

February is AMD Awareness & Low Vision Month

  Here are some helpful tips to help.   1. Speak to your eye care professional to see if there are any new treatments available. 2. If you have lost…

February is AMD Awareness & Low Vision Month

Feb 13, 2023

AMD-See the Day

New services available at CVS in Tampa, FL Don’t let age dim your vision. As we age, our eyes change, but not all changes are “natural” or inevitable-Related Macular Degeneration,…

AMD-See the Day

Feb 9, 2023

FDA grants fast track designation for retinitis pigmentosa treatment

EA-2353 for the treatment of retinitis pigmentosa received fast-track designation from the FDA, according to a press release from Endogena Therapeutics. The gene-independent treatment approach activates endogenous retinal stem and progenitor…

FDA grants fast track designation for retinitis pigmentosa treatment

Feb 7, 2023

February is Macular Degeneration & Low Vision Awareness month

Low vision looks different for everyone — literally. These are four examples of what blindness can look like. Blindness is a spectrum, it is rarely absolute, and understanding the low…

February is Macular Degeneration & Low Vision Awareness month

Jan 25, 2023

More Than 1 in 4 Americans Over 70 Has Impaired Vision

by: Dennis Thompson Key Takeaways More than a quarter of U.S. seniors is living with an untreated vision problem — nearsightedness, farsightedness, or impaired contrast sensitivity Trouble reading? This can…

More Than 1 in 4 Americans Over 70 Has Impaired Vision

Jan 17, 2023

Glaucoma Awareness Month

Glaucoma is a leading cause of vision loss and blindness in the United States. Glaucoma has no early symptoms — that’s why half of the people with glaucoma don’t know…

Glaucoma Awareness Month

Jan 17, 2023

Clinical Trials & Early Access Program- Apellis

Clinical trials are a critical component of our efforts to deliver innovative therapies to people living with serious diseases, and they help to determine whether a new therapy is safe…

Clinical Trials & Early Access Program- Apellis

Jan 17, 2023

Tampa Vision Seminar

Join the Macular Degeneration Association and the Foundation Fighting Blindness, Tampa Chapter at TPepin’s Hospitality Centre. Secure your spot today! Tampa Vision Seminar Saturday, February 4, 2023 9:00 a.m. –…

Tampa Vision Seminar

Jan 16, 2023

Health Benefits of Dates: A Sweet Superfood for a Healthy Life

By Happy Sharer Introduction Dates are a popular sweet snack that has been enjoyed around the world for thousands of years. They are a type of dried fruit that is…

Health Benefits of Dates: A Sweet Superfood for a Healthy Life

Jan 10, 2023

False Positive Neovascular AMD Results May Foretell Future Conversion

by: Lauren Dembeck, PhD ForeseeHome false positive alerts in fellow eyes to eyes with neovascular age-related macular degeneration predict future conversions. When a patient with previously diagnosed neovascular age-related macular…

False Positive Neovascular AMD Results May Foretell Future Conversion

Jan 2, 2023

The Macular Degeneration Association is proud to highlight Medical Board Member, JEREMIAH BROWN, JR., MS, MD

Dr. Jeremiah Brown, Jr. is a board-certified ophthalmologist with more than 10 years of practice experience as a Vitreoretinal Surgeon. He founded the Brown Retina Institute in 2010 to establish…

The Macular Degeneration Association is proud to highlight Medical Board Member, JEREMIAH BROWN, JR., MS, MD

Jan 2, 2023

Late-Stage AMD Patients Needed: Study Underway to Evaluate a New-Generation Implantable Miniature Telescope

In 2010, the U.S. Food and Drug Administration (FDA) approved a novel device from Samsara Vision called the Implantable Miniature Telescope (IMT). The purpose of this device is to magnify…

Late-Stage AMD Patients Needed: Study Underway to Evaluate a New-Generation Implantable Miniature Telescope

Jan 1, 2023

Happy New Year 2023

The Macular Degeneration Association wanted to wish everyone a very Happy 2023.

Happy New Year 2023

Dec 27, 2022

More Than an Eye Exam: How Nutrition and Lifestyle Can Improve Eye Health

We have all heard the saying, “You are what you eat,” and nutrition gives us the power to choose our health outcome. by: Mila Ioussifova, OD, FAAO Nutrition plays a…

More Than an Eye Exam: How Nutrition and Lifestyle Can Improve Eye Health

Dec 23, 2022

Retina Specialist and Optometrist Comanagement of AMD Patients

Eye care professionals can partner for optimal patient care. By Jeffry Gerson, OD; Rishi P. Singh, MD Although age-related macular degeneration (AMD) is a leading cause of vision loss for Americans 50…

Retina Specialist and Optometrist Comanagement of AMD Patients

Dec 19, 2022

My Accessible Kitchen Tour

In this video, I take a tour through my kitchen and show all the gadgets and tricks I use.  

My Accessible Kitchen Tour

Dec 14, 2022

AmazonSmile

You can help support the Macular Degeneration Association at no additional cost. Simply add us to your charity choice on AmazonSmile. Thank you.

AmazonSmile

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.